Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.

The future of clinical development is digital. From wearable sensors to AI-powered analysis, sponsors who embrace digital strategies will gain faster decisions, better data, and stronger regulatory confidence. Get a ste...

Site-centricity is no longer optional. ICON’s whitepaper reveals how early engagement and dedicated support drive faster, more predictable trials. Download here: https://ow.ly/vSms50XB73q

CRAs are no longer just monitors, they’re strategic site partners. Discover how tech is driving this shift in this ACT article featuring ICON’s Helen Yeardley. https://ow.ly/3qob50XB6Vo

Driving compliance in fully remote Alzheimer’s trials is complex, ICON Concierge Services makes it possible. In a pre-clinical study with 600+ participants and over 50 ePROs per patient, Concierge direct-to-patient serv...

Successful execution of a cardiovascular outcome trial depends on patient retention — but there are other areas of a CVOT where considering the human element is crucial as well. Explore how people impact multiple dimensi...

Learn the pros and cons of different AI models for SaMDs. The right model and data training sets are essential to develop your AI-enabled device. Our latest whitepaper lays out the best practices for data and AI models...

What should you consider when choosing a training dataset for your AI-enabled SaMD? Our whitepaper has the answers. Learn about AI models and data best practices and plan for your FDA Pre-Sub. Download it today. https://...

Central laboratories are under more pressure than ever. Increasingly complex protocols, frequent amendments, and growing data demands require speed, agility, and uncompromising scientific integrity. At ICON Laboratories,...

The annual J.P. Morgan Healthcare Conference convenes thousands of healthcare investors, global industry leaders and technology innovators to explore the key trends shaping the industry in 2026 and beyond. If you would ...

Early phase neurodegenerative trials require careful planning, a patient-first approach, and biomarker strategies that drive progress. Tune in to our recent ASCPT-hosted webinar, where we explored: - How to define target...

Site activation can take months. Learn how ICON is helping sponsors cut timelines in half with AI-powered tools and site-centric planning. Read the whitepaper: https://ow.ly/3w8u50XB70W